PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2006
CASE
AUTH/1895/10/06 AstraZeneca

AstraZeneca: overnight stay for short regional meeting ruled inappropriate (AUTH/1895/10/06)

Anonymous complaint about AstraZeneca-sponsored psychiatrist meetings. Panel upheld one breach: overnight accommodation for a 4.5-hour Coventry meeting was not justified (Clause 19.1).…

2007
CASE
AUTH/1962/2/07 AstraZeneca ⭐ Case of the Week

AUTH/1962/2/07: PCT adviser v AstraZeneca – Symbicort budget impact model presented to practice managers (no breach)

A PCT adviser challenged AstraZeneca’s Symbicort budget impact presentation to GP practice managers and meeting sponsorship. Panel found the audience and hospitality…

2007
CASE
AUTH/1957/2/07 Sanofi

Sanofi-Aventis held responsible for athlete’s positive Lantus comments to the public at a hospital fun day (AUTH/1957/2/07)

A sponsored athlete with diabetes spoke to parents at a hospital fun day and repeatedly praised Lantus. PMCPA held Sanofi-Aventis responsible and…

2006
CASE
AUTH/1930/12/06 Pliva Pharma

AUTH/1930/12/06: University Hospital Principal Pharmacist v Pliva Pharma – email chase about discounts and generics (No breach)

A hospital pharmacist complained about a Pliva email to a colleague chasing action after a discounts/generics meeting. Panel found Cystistat was a…

Gamble

Procter & Gamble: β€˜Dear Doctor’ mesalazine letterβ€”no disguised promotion, but misleading sponsorship wording breached Clause 9.1

GPs alleged a professor’s mesalazine letter (P&G educational grant) was disguised promotion for Asacol. Panel found no promotion/disguised promotion, but ruled Clause…

2006
CASE
AUTH/1868/7/06 Janssen

Doctor v Janssen-Cilag: Tramacet NNT comparison found misleading (AUTH/1868/7/06)

A Tramacet e-ad compared NNTs but omitted the commonly used co-codamol 60/1000 NNT (2.2), making Tramacet look more favourable. Breach of Clauses…

2017
CASE
AUTH/3006/12/17 Eli Lilly ⭐ Case of the Week

PMCPA AUTH/3006/12/17: Director v Lilly (Trulicity) – clinical trial disclosure

PMCPA case AUTH/3006/12/17 (Director v Lilly) concerning clinical trial disclosure for Trulicity. Outcome: No breach; matter was outwith the scope of the…

2015
CASE
AUTH/2812/12/15 Mylan

AUTH/2812/12/15: Mylan frozen yoghurt at ESC congress stand ruled beyond subsistence

At ESC Congress 2015, Mylan offered frozen yoghurt from its exhibition stand. The Panel ruled this went beyond subsistence hospitality (Clause 22.1)…

2014
CASE
AUTH/2691/1/14 Otsuka

AUTH/2691/1/14: Member of the public v Otsuka (Clinical trial disclosure – Cimiza) – No breach (outwith scope)

PMCPA case AUTH/2691/1/14: complaint about clinical trial disclosure for Cimiza. The matter was found to be outwith the scope of the ABPI…

2013
CASE
AUTH/2630/8/13 Takeda

Takeda: Anonymous complaint about meeting sponsorship (out of scope; no breach) β€” AUTH/2630/8/13

Anonymous complaint about Takeda meeting sponsorship. PMCPA recorded the matter as outwith the scope of the ABPI Code, so no case report…

2006
CASE
AUTH/1831/4/06 Janssen

AUTH/1831/4/06: GP v Janssen-Cilag β€” Durogesic DTrans promotional email (No breach)

A GP said a Durogesic DTrans promotional email was unsolicited and misused the NHS net. Janssen said it was sent only to…

2018
CASE
AUTH/3131/12/18 Napp ⭐ Case of the Week

AUTH/3131/12/18: Anonymous (non-contactable) v Napp β€” social media meeting adverts and sponsorship disclosure (No breach)

Complaint alleged Facebook/Twitter meeting adverts lacked sponsorship statements and reached the public. Panel initially found a Clause 22.4 breach for one Facebook…

Beacon Pharmaceuticals

GP v Beacon Pharmaceuticals: unsolicited promotional email for Episenta (breach of Clause 9.9)

Beacon was held responsible for a third-party agency’s promotional email about Episenta sent without proven prior consent. The Panel found the β€œopt-in”…

2006
CASE
AUTH/1801/2/06 GlaxoSmithKline

GSK breach for directing HCPs (and indirectly the public) to a patient group website containing unlicensed and misleading ropinirole messages (AUTH/1801/2/06)

GSK ran RLS disease-awareness ads in GP journals pointing to a patient group website. The site later included content implying ropinirole was…

2006
CASE
AUTH/1911/11/06 Gamble

P&G/Sanofi slide kit on Bonviva: disparagement and unclear origin of FDA-derived analyses (AUTH/1911/11/06, AUTH/1912/11/06)

Roche/GSK challenged a competitor slide kit on Bonviva using FDA-review material. Panel found it disparaged Bonviva and misled readers by blurring FDA…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training